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Oral Isotretinoin Therapy
Use in a Patient With Multiple Cutaneous
Squamous Cell Carcinomas and Keratoacanthomas
Norman Levine, MD; Richard C. Miller, MD; Frank Louis Meyskens, Jr, MD
\s=b\An 83-year-old woman with multiple squamous cell
carcinomas and keratoacanthomas of the legs was
treated with orally administered isotretinoin (13 cis\x=req-\
retinoic acid). Complete regression of the tumors was
noted during the initial six-month treatment period. In the
subsequent 36 months, four new cutaneous tumors were
excised. There have been no recurrences of lesions that
regressed while the patient was receiving retinoid thera-
py.
(Arch Dermatol 1984;120:1215-1217)
Retinoids are chemically related to vitamin A andhave many biologic effects, including antitumor
actions, particularly against cutaneous neoplasms.17
In the present study, oral isotretinoin (13 cts-retinoic
acid) therapy without surgery was used to treat a
patient with multiple cutaneous squamous cell carci¬
nomas (SCCs) and keratoacanthomas (KAs).
REPORT OF A CASE
An 83-year-old woman had a skin tumor develop on the
left forearm in 1975 at the age of 77 years. The biopsy
specimen disclosed SCC. Over the next four years, 19
additional tumors on the legs, arms, and forearms devel¬
oped; these were subsequently excised and found to be
either SCC (Fig 1) or KA.
The patient was first seen by one of us (R.C.M.) in 1980
for six well-defined, hyperkeratotic, approximately 1.5- to
2.5-cm nodules on the lower legs. Biopsy specimens of two
of these tumors disclosed the microscopic findings of SCC,
and a third disclosed the changes of a KA (Fig 2). The
remaining three lesions were removed without microscopic
examination because of the clinical similarity to the
lesions from which biopsy specimens had been taken. Over
the next three months, the patient noted the appearance of
approximately 20 additional 0.5- to 2.0-cm papules and
nodules over the legs and was referred to the University of
Arizona Health Sciences Center, Tucson, for oral isotreti¬
noin therapy. At no time prior to the initiation of retinoid
treatment did any of her tumors spontaneously remit.
The patient was in otherwise good health and was taking
no medications. She gave no history of exposure to arsenic
or other potential carcinogens. There was no family histo¬
ry of a similar cutaneous problem.
Examination of the skin disclosed multiple 0.5- to 2.0-cm
papules and nodules, all arising from an erythematous
base. Many of the lesions had central keratotic plugs, and
some of the lesions had erosions or shallow ulcérations
(Fig 3, top).
METHODS
After informed consent had been obtained in accordance
with established hospital procedures, the patient began to
take isotretinoin, 2 mg/kg/day. She continued with this
regimen for six months and underwent monthly complete
blood cell counts, serum liver function studies, and serum
triglycéride and cholesterol levels.
RESULTS
Within two weeks of starting oral isotretinoin
therapy, many of the smaller lesions had flattened
considerably and by six weeks had resolved com¬
pletely. The larger tumors showed noticeable regres¬
sion after six weeks, and all but a single lesion on the
posterior calf had disappeared after six months of
therapy (Fig 3, bottom). The solitary remaining
tumor was excised after the six-month retinoid
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Fig 1.—Biopsy specimen of cutaneous
squamous cell carcinoma shows inva¬
sion of dermis by epidermal masses with
horn pearls (hematoxylin-eosin, original
magnification X45).
Fig 3.—Top, Patient's pretreatment condition with numerous
tumors on right anterior leg. Bottom, Patient's right leg after six
months of isotretinoin therapy. Tumors have resolved, leaving
depressed hypopigmented scars.
Fig 2.—Biopsy specimen of keratoacanthoma shows keratin-filled crater and
irregular epidermal proliferation into dermis (hematoxylin-eosin, original magnification
X20).
treatment period. Microscopic examination disclosed
that it was a KA.
In the succeeding 36 months after isotretinoin
therapy was discontinued, three SCCs and one KA
developed in areas not previously involved. These
lesions were surgically removed.
COMMENT
A patient with multiple cutaneous SCCs and KAs
responded to oral isotretinoin therapy with complete
clearing of almost all lesions. Twenty tumors
resolved completely over a six-month course of ther¬
apy with no recurrence of these lesions in the
subsequent 36 months of observation. A preliminary
report of this case was reported previously in tabular
form without further description.8
A number of different mechanisms of retinoid
antitumor action have been proposed, including
effects on epithelial differentiation,9 steroid hor¬
mone-like effects in the nucleus,10 immunomodula-
tion,"12 membrane effects,13 and oncogene-interfer-
ence properties.'4 In addition, several clinical studies
have demonstrated retinoid antineoplastic re¬
sponses. Koch3 reported a 45% remission rate of
multifocal and advanced leukoplakia of the oral
mucosa with an aromatic retinoid. In 1982, Moriarity
et al" reported that 37 of 44 patients with actinic
kératoses responded to four months of aromatic
retinoic treatment. Peck et al5 noted regression of
basal cell carcinomas with isotretinoin therapy. Le¬
vine and Meyskens6 reported the cases of two
patients with multiple foci of cutaneous metastatic
melanoma that responded to topical tretinoin (trans
retinoic acid).6 Haydey et al7 successfully treated a
patient with multiple KAs with oral isotretinoin
therapy, which prevented the recurrence of tumors
that had recently been surgically excised. Our case is
the second one reported in which the patient had
multiple KAs successfully treated with oral isotreti¬
noin therapy; however, it differs from the first
report in that no pretherapy surgical excisions were
needed to effect a cure.7
Our patient had only four additional lesions devel¬
op since therapy was discontinued. It is possible that
the isotretinoin acted as a chemopreventive agent as
well as a chemotherapeutic modality. The role of
retinoids in cancer prevention has been suggested,15
and there are substantial in vitro data,16 and in vivo
observations1718 to support this contention.
Could these tumors have regressed spontaneously
in spite of retinoid therapy? This is highly unlikely,
since the patient had never had a previous lesion that
disappeared without therapy; the lesions regressed
as a group shortly after treatment was begun, and
the biologic behavior of SCC is such that it shows
little or no tendency to spontaneous resolution. We
believe that in selected cases of multiple KAs and/or
SCCs, where surgical excision of the lesions is not
possible, or feasible, isotretinoin may be a useful
therapeutic modality.
This investigation was supported in part by grant CA 27502
from the National Cancer Institute.
The isotretinoin was supplied by Hoffmann-La Roche, Inc,
Nutley, NJ.
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